2021’s crystal ball: Six AI predictions from Aktana management that will shape a new commercial model.
The pharmaceutical industry can expect continued pricing pressures in 2021, with only a slight nod of respect from the general public given to its activities in generating vaccines and therapies to fight the pandemic.
The medical cannabis market in the United States, even with all of its restrictions, continues to be a fertile area not only for dispensaries, but pharma companies developing cannabis-derived drugs; and proponents say further growth can be generated by educating physicians about medical cannabis.
It’s a word that’s been popping up more and more frequently in the pharma context, but not everyone understands what it is and what it can do. We asked the experts to explain blockchain.
As large pharmaceutical companies increasingly look to outsource aspects of drug discovery and development to external collaborators, the ability to identify the right partnership candidates before competitors has become critical.
The healthcare industry is increasingly focusing on niche patient populations. However, finding hard-to-reach rare disease patients is difficult and keeping them engaged over time even more so. Could machine learning platforms that deliver personalized experiences for patients and caregivers be part of the answer?
Everyone knows the terms “machine learning” and “artificial intelligence.” Few can define them, much less explain their inestimable value to clinical trials. So, it’s not surprising that, despite their ability to minimize risk, improve safety, condense timelines, and save costs, these technology tools are not widely used by the clinical trial industry.
Zolgensma’s successful market uptake by payers may hold lessons for other manufacturers of costly gene therapies.
Brands and agencies are finding creative ways to explore the patient experience by placing viewers inside a hypothetical patient’s personal space.
The COVID-19 virus has fundamentally changed how we go about our daily lives on both a personal and professional level. We are becoming more accustomed to social distancing and virtual interaction with our friends, family members, loved ones, and colleagues. The change in behavior seems to be an easier adjustment in our personal lives than professional lives, but both have been impacted as a result of the virus.
